 Matthew Witkowski
Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2025 | 80 | 3.110 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2023 | 289 | 2.130 |
Why?
| | Lymphoma, B-Cell | 2 | 2023 | 106 | 1.480 |
Why?
| | Tumor Microenvironment | 6 | 2023 | 674 | 1.200 |
Why?
| | Ikaros Transcription Factor | 2 | 2017 | 24 | 0.980 |
Why?
| | Leukemia, Myeloid, Acute | 6 | 2023 | 630 | 0.930 |
Why?
| | Bone Marrow | 4 | 2022 | 286 | 0.920 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2025 | 26 | 0.870 |
Why?
| | Leukemia | 3 | 2022 | 240 | 0.840 |
Why?
| | Burkitt Lymphoma | 1 | 2022 | 60 | 0.750 |
Why?
| | Monocytes | 2 | 2023 | 563 | 0.710 |
Why?
| | Immunity | 1 | 2019 | 143 | 0.600 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 190 | 0.540 |
Why?
| | Immunotherapy | 2 | 2022 | 641 | 0.480 |
Why?
| | Receptors, Notch | 2 | 2019 | 88 | 0.470 |
Why?
| | F-Box Proteins | 1 | 2015 | 23 | 0.460 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 1079 | 0.420 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2015 | 175 | 0.410 |
Why?
| | Immunotherapy, Adoptive | 3 | 2022 | 327 | 0.400 |
Why?
| | Single-Cell Analysis | 4 | 2025 | 313 | 0.350 |
Why?
| | Stem Cell Niche | 3 | 2020 | 54 | 0.350 |
Why?
| | Cell Cycle Proteins | 1 | 2015 | 617 | 0.350 |
Why?
| | Trans-Activators | 2 | 2022 | 398 | 0.290 |
Why?
| | Biomarkers, Tumor | 1 | 2015 | 1276 | 0.280 |
Why?
| | T-Lymphocytes | 4 | 2022 | 1996 | 0.270 |
Why?
| | Animals | 14 | 2025 | 36940 | 0.270 |
Why?
| | Flow Cytometry | 2 | 2023 | 1178 | 0.240 |
Why?
| | Chromatin Assembly and Disassembly | 2 | 2024 | 104 | 0.240 |
Why?
| | Cell Lineage | 2 | 2025 | 350 | 0.240 |
Why?
| | Hematopoietic Stem Cells | 2 | 2019 | 406 | 0.240 |
Why?
| | Multipotent Stem Cells | 1 | 2025 | 20 | 0.240 |
Why?
| | Antigens, CD19 | 2 | 2022 | 123 | 0.230 |
Why?
| | CD47 Antigen | 1 | 2025 | 38 | 0.230 |
Why?
| | Proto-Oncogene Proteins | 2 | 2019 | 648 | 0.230 |
Why?
| | Diphtheria Toxin | 1 | 2025 | 66 | 0.230 |
Why?
| | Immunotoxins | 1 | 2025 | 55 | 0.230 |
Why?
| | Lymphopoiesis | 1 | 2024 | 26 | 0.220 |
Why?
| | Clonal Evolution | 1 | 2024 | 45 | 0.220 |
Why?
| | Mice | 11 | 2025 | 17787 | 0.210 |
Why?
| | Humans | 23 | 2025 | 137585 | 0.210 |
Why?
| | Chromatin | 2 | 2024 | 519 | 0.210 |
Why?
| | Cell Differentiation | 4 | 2021 | 1991 | 0.200 |
Why?
| | Cleavage And Polyadenylation Specificity Factor | 1 | 2022 | 9 | 0.200 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2023 | 126 | 0.190 |
Why?
| | Osteoblasts | 2 | 2020 | 126 | 0.190 |
Why?
| | Valine-tRNA Ligase | 1 | 2021 | 1 | 0.190 |
Why?
| | Phospholipase C gamma | 1 | 2022 | 29 | 0.190 |
Why?
| | Polyadenylation | 1 | 2022 | 42 | 0.190 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2024 | 327 | 0.190 |
Why?
| | Valine | 1 | 2021 | 82 | 0.180 |
Why?
| | Hematopoiesis | 2 | 2021 | 192 | 0.180 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2022 | 73 | 0.180 |
Why?
| | Adipocytes | 2 | 2020 | 222 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 156 | 0.170 |
Why?
| | Antigens, Surface | 1 | 2021 | 154 | 0.170 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 500 | 0.160 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2022 | 801 | 0.160 |
Why?
| | Cell Transdifferentiation | 1 | 2019 | 31 | 0.160 |
Why?
| | Mutation | 3 | 2022 | 3958 | 0.150 |
Why?
| | Bone Marrow Transplantation | 1 | 2020 | 286 | 0.150 |
Why?
| | B-Lymphocytes | 2 | 2025 | 847 | 0.150 |
Why?
| | Cellular Microenvironment | 1 | 2019 | 84 | 0.150 |
Why?
| | Cell Line, Tumor | 4 | 2025 | 3412 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2019 | 347 | 0.140 |
Why?
| | Signal Transduction | 4 | 2022 | 5079 | 0.140 |
Why?
| | Catenins | 1 | 2017 | 6 | 0.130 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2017 | 69 | 0.130 |
Why?
| | bcl-2 Homologous Antagonist-Killer Protein | 1 | 2016 | 15 | 0.130 |
Why?
| | Endothelium, Vascular | 2 | 2020 | 927 | 0.130 |
Why?
| | Molecular Targeted Therapy | 1 | 2019 | 411 | 0.130 |
Why?
| | bcl-X Protein | 1 | 2016 | 43 | 0.130 |
Why?
| | Vitamins | 1 | 2017 | 185 | 0.120 |
Why?
| | Ascorbic Acid | 1 | 2017 | 177 | 0.120 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 916 | 0.120 |
Why?
| | Myelodysplastic Syndromes | 1 | 2017 | 135 | 0.120 |
Why?
| | Proteome | 1 | 2020 | 472 | 0.120 |
Why?
| | Survival Rate | 1 | 2020 | 1972 | 0.120 |
Why?
| | Repressor Proteins | 1 | 2019 | 427 | 0.120 |
Why?
| | Prognosis | 2 | 2023 | 4030 | 0.120 |
Why?
| | F-Box-WD Repeat-Containing Protein 7 | 1 | 2015 | 6 | 0.120 |
Why?
| | Neoplastic Stem Cells | 1 | 2019 | 399 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2019 | 718 | 0.120 |
Why?
| | Homeodomain Proteins | 1 | 2019 | 506 | 0.120 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 385 | 0.110 |
Why?
| | Chromatin Immunoprecipitation | 1 | 2015 | 138 | 0.110 |
Why?
| | PAX5 Transcription Factor | 1 | 2014 | 14 | 0.110 |
Why?
| | RNA, Messenger | 1 | 2022 | 2833 | 0.110 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2014 | 40 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2017 | 434 | 0.110 |
Why?
| | RNA-Binding Proteins | 1 | 2017 | 422 | 0.100 |
Why?
| | Mice, Transgenic | 2 | 2015 | 2167 | 0.100 |
Why?
| | Blood Platelets | 1 | 2016 | 408 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3556 | 0.100 |
Why?
| | Blotting, Western | 1 | 2015 | 1226 | 0.090 |
Why?
| | Mice, Inbred C57BL | 2 | 2020 | 5757 | 0.090 |
Why?
| | Antineoplastic Agents | 2 | 2020 | 2129 | 0.090 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2015 | 539 | 0.090 |
Why?
| | Membrane Proteins | 1 | 2017 | 1164 | 0.080 |
Why?
| | Recurrence | 2 | 2024 | 1060 | 0.080 |
Why?
| | DNA-Binding Proteins | 1 | 2017 | 1502 | 0.080 |
Why?
| | Child, Preschool | 2 | 2024 | 11074 | 0.080 |
Why?
| | Carcinogenesis | 2 | 2019 | 217 | 0.070 |
Why?
| | Child | 3 | 2024 | 21935 | 0.070 |
Why?
| | Apoptosis | 1 | 2016 | 2553 | 0.070 |
Why?
| | Transcriptome | 2 | 2025 | 971 | 0.060 |
Why?
| | Infant | 1 | 2020 | 9465 | 0.060 |
Why?
| | Adolescent | 2 | 2024 | 21513 | 0.060 |
Why?
| | Gene Knockdown Techniques | 2 | 2017 | 327 | 0.060 |
Why?
| | Female | 5 | 2025 | 73304 | 0.050 |
Why?
| | Mice, SCID | 1 | 2025 | 367 | 0.050 |
Why?
| | Translocation, Genetic | 1 | 2024 | 105 | 0.050 |
Why?
| | Young Adult | 1 | 2020 | 13209 | 0.050 |
Why?
| | Mice, Inbred NOD | 1 | 2025 | 601 | 0.050 |
Why?
| | Oncogenes | 1 | 2023 | 116 | 0.050 |
Why?
| | Male | 4 | 2025 | 67762 | 0.050 |
Why?
| | Retrospective Studies | 1 | 2020 | 15657 | 0.050 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2021 | 14 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2025 | 872 | 0.050 |
Why?
| | Electron Transport Complex I | 1 | 2021 | 41 | 0.050 |
Why?
| | Biological Availability | 1 | 2021 | 148 | 0.050 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2022 | 130 | 0.040 |
Why?
| | Adult | 2 | 2022 | 37929 | 0.040 |
Why?
| | Transcriptional Activation | 1 | 2023 | 378 | 0.040 |
Why?
| | Clustered Regularly Interspaced Short Palindromic Repeats | 1 | 2021 | 31 | 0.040 |
Why?
| | Oxidative Phosphorylation | 1 | 2021 | 193 | 0.040 |
Why?
| | RNA, Transfer | 1 | 2021 | 138 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2021 | 233 | 0.040 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2020 | 40 | 0.040 |
Why?
| | Lymphocytes | 1 | 2023 | 397 | 0.040 |
Why?
| | CRISPR-Cas Systems | 1 | 2021 | 125 | 0.040 |
Why?
| | Piperidines | 1 | 2022 | 206 | 0.040 |
Why?
| | Adenine | 1 | 2022 | 271 | 0.040 |
Why?
| | Acute Disease | 1 | 2023 | 1007 | 0.040 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2022 | 385 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2607 | 0.040 |
Why?
| | Cells, Cultured | 2 | 2019 | 4193 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2022 | 452 | 0.040 |
Why?
| | Cell Plasticity | 1 | 2019 | 35 | 0.040 |
Why?
| | Receptors, Interferon | 1 | 2019 | 52 | 0.040 |
Why?
| | Tretinoin | 1 | 2019 | 123 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 148 | 0.040 |
Why?
| | Calcium-Binding Proteins | 1 | 2019 | 218 | 0.030 |
Why?
| | Dioxygenases | 1 | 2017 | 26 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2017 | 194 | 0.030 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 50 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2017 | 257 | 0.030 |
Why?
| | Tumor Suppressor Proteins | 1 | 2019 | 327 | 0.030 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2019 | 430 | 0.030 |
Why?
| | Cell Death | 1 | 2017 | 374 | 0.030 |
Why?
| | Stress, Physiological | 1 | 2019 | 443 | 0.030 |
Why?
| | Mitochondria | 1 | 2021 | 948 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1719 | 0.030 |
Why?
| | Protein Domains | 1 | 2016 | 289 | 0.030 |
Why?
| | Genes, myc | 1 | 2014 | 48 | 0.030 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 57 | 0.030 |
Why?
| | Diet | 1 | 2021 | 1278 | 0.030 |
Why?
| | Risk Assessment | 1 | 2022 | 3457 | 0.030 |
Why?
| | Protein Conformation | 1 | 2016 | 934 | 0.030 |
Why?
| | Cell Survival | 1 | 2016 | 1120 | 0.020 |
Why?
| | DNA Methylation | 1 | 2017 | 643 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2019 | 3015 | 0.020 |
Why?
| | Inflammation | 1 | 2022 | 2837 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2017 | 1457 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2847 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2224 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2014 | 1396 | 0.020 |
Why?
| | Middle Aged | 1 | 2022 | 33479 | 0.010 |
Why?
|
|
Witkowski's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|